Kintara Therapeutics is a clinical stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. Our lead program, VAL-083 for Glioblastoma GBM), is in an international registrational study through the Global Coalition for Adaptive Research (GCAR). We are expecting topline data from our VAL-083 program in GBM around the end of 2023. We also have a program, REM-001, for Metastatic Cutaneous Breast Cancer. We recently paused our REM-001 and hope to restart the program after we receive additional funding.
Ticker:
KTRA
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2009
Main Therapeutic Focus:
Oncology
Lead Product in Development:
VAL-083
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
